First Patient Dosed in Dauntless-1 Ph 2 Clinical Trial of PMD-026 in Combination with Fulvestrant for RSK2-high Breast Cancer
“We are especially excited about our Phase 2 trial because PMD-026 has the potential to overcome CDK4/6 resistance based on pre-clinical and early clinical studies” said Sandi Dunn, PhD, Founder and CEO of Phoenix Molecular Designs. “In our Phase 1/1b monotherapy study, PMD-026 demonstrated favorable tolerability, with no peripheral neuropathy, hair loss, or hyperglycemia. Moreover, PMD-026 demonstrated a median progression free survival (mPFS) of 4.8 months in patients with RSK2-high tumors versus only 1.3 months in patients with RSK2-low tumors in a subset analysis of patients who had no more than five prior therapies. We believe that PMD-026 as a combination therapy represents a promising new approach to treating advanced breast cancer.”
Share:
More News
Taiho Oncology, Inc. completed a New Drug Application (NDA) submission to the U.S. Food and Drug Administration (FDA) for zipalertinib in combination with platinum-based chemotherapy for the treatment of patients with previously untreated, locally advanced or metastatic non-small cell lung cancer (NSCLC) harboring epidermal growth factor receptor (EGFR) exon 20
“This collaboration reflects our conviction that atebimetinib has the potential to become an essential backbone therapy in a broad range of combinations across MAPK-driven cancers,” said Ben Zeskind, Immuneering CEO and co-founder. “Atebimetinib’s unique tolerability profile and broad activity make it well suited to combine with a wide range of
“These final updated results provide continued evidence of the potential for γδ T cell therapies to drive activity and improve outcomes for patients,” said William Ho, CEO and co-founder of IN8bio. “The clinical outcomes and observed activity are supported by our correlative analysis, including histopathology, demonstrating the expansion and persistence
“Patients with RAS-mutated mCRC have no first-line therapies specifically approved for their disease, and Fast Track designation reflects the potential of onvansertib to address this serious unmet need,” said Mani Mohindru, PhD, President and Chief Executive Officer of Cardiff Oncology. “Our randomized Phase 2 data give us confidence that onvansertib